339 related articles for article (PubMed ID: 20976768)
1. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
[TBL] [Abstract][Full Text] [Related]
2. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
3. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
[TBL] [Abstract][Full Text] [Related]
4. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
Cornblath DR; Bienen EJ; Blight AR
Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
[TBL] [Abstract][Full Text] [Related]
5. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL; Sidovar MF; Coleman CI
Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
[TBL] [Abstract][Full Text] [Related]
7. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
Pikoulas TE; Fuller MA
Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
[TBL] [Abstract][Full Text] [Related]
8. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
Coleman CI; Sobieraj DM; Marinucci LN
Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
[TBL] [Abstract][Full Text] [Related]
9. Dalfampridine extended release: in multiple sclerosis.
Chwieduk CM; Keating GM
CNS Drugs; 2010 Oct; 24(10):883-91. PubMed ID: 20839898
[TBL] [Abstract][Full Text] [Related]
10. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
[TBL] [Abstract][Full Text] [Related]
11. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
Blight AR; Henney HR; Cohen R
Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of dalfampridine in patients with multiple sclerosis.
Ruck T; Bittner S; Simon OJ; Göbel K; Wiendl H; Schilling M; Meuth SG
J Neurol Sci; 2014 Feb; 337(1-2):18-24. PubMed ID: 24290498
[TBL] [Abstract][Full Text] [Related]
13. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
Egeberg MD; Oh CY; Bainbridge JL
Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
[TBL] [Abstract][Full Text] [Related]
14. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
[TBL] [Abstract][Full Text] [Related]
15. Assessing dalfampridine efficacy in the physician's office.
Raffel JB; Malik O; Nicholas RS
Mult Scler; 2014 Jan; 20(1):24-6. PubMed ID: 23727943
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis.
Weir S; Torkin R; Henney HR
Curr Med Res Opin; 2013 Dec; 29(12):1627-36. PubMed ID: 23157467
[TBL] [Abstract][Full Text] [Related]
17. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
Dunn J; Blight A
Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
[TBL] [Abstract][Full Text] [Related]
18. Sustained release oral fampridine in the treatment of multiple sclerosis.
Kachuck NJ
Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
[TBL] [Abstract][Full Text] [Related]
19. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
Fernandez O; Berger T; Hartung HP; Putzki N
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
[TBL] [Abstract][Full Text] [Related]
20. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
van Diemen HA; Polman CH; van Dongen TM; van Loenen AC; Nauta JJ; Taphoorn MJ; van Walbeek HK; Koetsier JC
Ann Neurol; 1992 Aug; 32(2):123-30. PubMed ID: 1510353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
